Fig. 8

LncRNA PART1 promotes gefitinib resistance in vivo. a Photographs of tumors that developed in xenograft transplanted nude mouse tumor models treated orally with once daily 150 mg/kg gefitinib or 1% Tween80 as control for four weeks in different groups. The group settings are as follows: Group I (Lv-PART1-transfected cells + gefitinib treatment), Group II (Lv-PART1-transfected cells + 1% Tween80), Group II (Lv-NC-transfected cells + gefitinib treatment), Group III (Lv-NC-transfected cells + 1% Tween80). b Weights of tumors that developed in xenografts from different groups. ^*P < 0.05, ^***P < 0.001 compared to respective groups. c IHC analysis of expression levels of respective apoptosis markers in group I and group III. ^*P < 0.05, ^**P < 0.01 compared to Group III